Informações principais
Sobre o conteúdo
The objective of this course is to offer an integrated overview of vaccinology, from public health and scientific data justifying the development of a vaccine, to its delivery to the populations in the context of industrialized and developing countries.
Dedicated to candidates with a medical or scientific background who are interested in all aspects of vaccinology: medical and public health students, scientific Master II and PhD students (Immunology, Microbiology), physicians, pharmacists, veterinarians and other health professionals.
The MOOC is composed of 31 lectures presenting historical aspects of vaccines, immunology and design of vaccines, basic principles of preclinical and clinical development, an update of vaccine development for the major infectious diseases, and the future challenges of vaccinology.
L'objectif de ce cours est d'offrir une vision intégrée de la vaccinologie, allant de la santé publique et des données scientifiques qui justifient le développement d'un vaccin, jusqu'à sa distribution aux populations dans le contexte des pays industrialisés et en développement.
Destiné aux personnes ayant une formation médicale ou scientifique qui s'intéressent à tous les aspects de la vaccinologie: étudiants en médecine et en santé publique, Masters scientifiques et doctorants (immunologie, microbiologie), médecins, pharmaciens, vétérinaires et autres professionnels de santé.
Le MOOC est composé de 31 séquences présentant les aspects historiques des vaccins, l'immunologie et la conception des vaccins, les principes de base du développement préclinique et clinique, une mise à jour du développement des vaccins pour les principales maladies infectieuses, et les futurs défis de la vaccinologie.
Pré-requisito
Background in microbiology, immunology, public health
Connaissances en microbiology, immunology, santé publique.
Programa de estudos
- History of vaccines including IP
- Smallpox eradication
- Polio eradication
- Modeling in vaccinology
- Antigen discovery
- Immune memory of vaccines
- Vaccines for pregnant women
- Vaccines for neonates
- Correlates of protection
- Adjuvants
- Delivery of vaccines
- On the importance of maintaining vaccine coverage
- Epidemiology post vaccination: pertussis vaccine example
- GMP production
- Immuno-monitoring
- Phase I/II clinical trials
- Phase III clinical trials
- Success of glycoconjugate vaccines
- Rotavirus vaccines
- HPV vaccines
- Influenza vaccines
- TB vaccines
- RSV vaccines
- HIV vaccines
- Malaria vaccines
- Vaccines against neglected parasites and worms
- Innovation in future vaccines
- Vaccines for the elderly
- Vaccine economics
- Globalization of vaccine production
- Vaccine implementation on the field
- Vaccine perception
Instrutores
Armelle Phalipon
Armelle Phalipon is a microbiologist leading a group within the Molecular Microbial Pathogenesis Unit, INSERM U786, at the Institut Pasteur, Paris, France. Working in the field of diarrheal diseases, her team is interested in deciphering the cross-talks between enteropathogenic bacteria and the host immune system. The main current studies aim at deciphering how Shigella, the bacterium responsible for bacillary dysentery, impacts on the development of the short-term, poorly effective protective immunity elicited in response to infection. Armelle Phalipon has a long-standing interest in combining fundamental and applied research. Indeed, in collaboration with Dr. Laurence Mulard (Institut Pasteur, Paris), she has designed a new type of Shigella vaccine candidate that will enter a phase 1 clinical trial in 2016 for proof of concept in humans. She is co-founder and co-director with Frédéric Tangy of the first International Vaccinology Course launched at the Pasteur Institute in 2008.
Frédéric Tangy
Frédéric Tangy, PhD, Dr.Sc., Director of Research at CNRS, is the head of the Viral Genomics and Vaccination Research Unit at Institut Pasteur, Paris (CNRS UMR-3569). After his PhD in 1980 and his Dr. Sc. in 1984 at Paris VI University he made his career as a virologist first at CNRS then at Institut Pasteur. He is co-director of the international Vaccinology course of Institut Pasteur, vice-president of the Scientific Council of Institut Pasteur, and member of ASM, ESGT, IAS, SFI. He is the author of 110 publications in international scientific journals and 19 international patents. In the recent years, he has developed two research programs: 1) generation of polyvalent viral attenuated vaccines based on a vector derived from measles vaccine. This project extends from the design of antigens and generation of recombinant vectors, to preclinical and clinical development in the field of HIV, dengue, chikungunya and malaria vaccines. 2) The second project investigates the interactions between viral and host proteins in a systematic way using functional genomic approaches such as high-throughput cloning, yeast two-hybrid, deep sequencing and high-throughput drug screening. This project aims at understanding at a molecular level the interactions between viral and host proteins and RNA in the field of paramyxoviruses. These observations lead to identify new drug targets and new determinants of pathogenicity/attenuation.
Criador do conteúdo
O Institut Pasteur é uma fundação francesa privada, sem fins lucrativos, com sede em Paris, dedicada ao estudo da biologia, dos microrganismos, das doenças e das vacinas.
Criado em 1888 graças a uma subscrição pública internacional, tem o nome de Louis Pasteur1, o seu fundador e primeiro diretor, que em 1885 desenvolveu a primeira vacina contra a raiva.
Durante mais de um século, o Instituto Pasteur esteve na vanguarda da luta contra as doenças infecciosas. Em 1983, este organismo internacional de investigação foi o primeiro a isolar o vírus da imunodeficiência humana (VIH), o vírus que causa a síndrome da imunodeficiência adquirida (SIDA). Ao longo dos anos, foi responsável por descobertas revolucionárias que permitiram à medicina controlar doenças virulentas como a difteria, o tétano, a tuberculose, a poliomielite, a gripe, a febre amarela, a peste epidémica, a hepatite B e a SIDA.
Plataforma
France Université Numérique est le diffuseur des cours en ligne des établissements d’enseignement supérieur français et de leurs partenaires.
Il opère plusieurs plateformes de diffusion, dont la plus connue, FUN MOOC, est la première plateforme académique francophone mondiale. Grâce à de nombreux établissements partenaires, cette plateforme propose un vaste catalogue de cours s’enrichissant de jour en jour avec des thématiques variées et d’actualité.
